Percentage of the 240 patients falling into the 2 primary genotypic groups at each of 16 loci
| Locus . | Genotype groups . | % in 1st genotype group . | % in 2nd genotype group . |
|---|---|---|---|
| CYP3A4*1B | AA vs AG and GG | 79.6 | 20.4 |
| CYP3A5*3 | AA and AG vs GG | 32.1 | 67.9 |
| GSTM1 deletion | Null vs nonnull | 42.5 | 57.5 |
| GSTP1 313A>G | AA and AG vs GG | 82.9 | 17.1 |
| GSTT1 deletion | Null vs nonnull | 15.8 | 84.2 |
| MDR1 exon 21 G>T/A | GG vs others | 36.7 | 63.3 |
| MDR1 exon 26 C>T | CC and CT vs TT | 76.3 | 23.7 |
| MTHFR 677C>T | CC vs CT and TT | 48.8 | 51.2 |
| MTHFR 1298A>C | AA vs AC and CC | 53.8 | 46.2 |
| NR3C1 1088A>G | AA vs AG | 96.7 | 3.3 |
| RFC 80A>G | AA and AG vs GG | 68.3 | 31.7 |
| TPMT combined genotypes | Others vs 238GG, 460GG, and 719AA | 5.8 | 94.2 |
| TYMS enhancer repeat | 3AND3 vs others | 31.7 | 68.3 |
| UGT1A1 promoter repeat | 7AND7 vs others | 10.4 | 87.9 |
| VDR Fokl T>C | CC vs CT and TT | 46.3 | 53.7 |
| VDR intron8 G>A | AA and AG vs GG | 54.2 | 45.8 |
| Locus . | Genotype groups . | % in 1st genotype group . | % in 2nd genotype group . |
|---|---|---|---|
| CYP3A4*1B | AA vs AG and GG | 79.6 | 20.4 |
| CYP3A5*3 | AA and AG vs GG | 32.1 | 67.9 |
| GSTM1 deletion | Null vs nonnull | 42.5 | 57.5 |
| GSTP1 313A>G | AA and AG vs GG | 82.9 | 17.1 |
| GSTT1 deletion | Null vs nonnull | 15.8 | 84.2 |
| MDR1 exon 21 G>T/A | GG vs others | 36.7 | 63.3 |
| MDR1 exon 26 C>T | CC and CT vs TT | 76.3 | 23.7 |
| MTHFR 677C>T | CC vs CT and TT | 48.8 | 51.2 |
| MTHFR 1298A>C | AA vs AC and CC | 53.8 | 46.2 |
| NR3C1 1088A>G | AA vs AG | 96.7 | 3.3 |
| RFC 80A>G | AA and AG vs GG | 68.3 | 31.7 |
| TPMT combined genotypes | Others vs 238GG, 460GG, and 719AA | 5.8 | 94.2 |
| TYMS enhancer repeat | 3AND3 vs others | 31.7 | 68.3 |
| UGT1A1 promoter repeat | 7AND7 vs others | 10.4 | 87.9 |
| VDR Fokl T>C | CC vs CT and TT | 46.3 | 53.7 |
| VDR intron8 G>A | AA and AG vs GG | 54.2 | 45.8 |